Sustained release small molecule drug formulation
AssigneeIndivior UK Limited
InventorsAndrew S. Luk, Gunjan H. Junnarkar, Guohua Chen
Life of this patent
Estimating the term…
Abstract
An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having a Cmax to Cmin ratio of less than 200 and a lag time less than 0.2.
Claims20
An injectable pharmaceutical composition comprising from about 10 wt % to about 30 wt % of risperidone base in a gel comprising:
- (i) from about 40 wt % to about 60 wt % of a copolymer of lactic acid and glycolic acid, wherein the lactic acid to glycolic acid monomer ratio is from about 100:0 to about 60:40, and wherein the copolymer has a number average molecular weight from about 5,000 Daltons to about 30,000 Daltons, and (ii) benzyl benzoate, benzyl alcohol, ethyl benzoate, triacetin, N-methyl-2-pyrrolidone, or a combination of two or more thereof.
An injectable pharmaceutical composition comprising from about 1 wt % to about 50 wt % of risperidone base in a gel comprising:
- (i) from about 5 wt % to about 80 wt % of a copolymer of lactic acid and glycolic acid, and (ii) benzyl benzoate, benzyl alcohol, ethyl benzoate, triacetin, N-methyl-2-pyrrolidone, or a combination of two or more thereof.
An injectable pharmaceutical composition comprising risperidone base in a gel comprising:
- (i) a copolymer of lactic acid and glycolic acid, and (ii) benzyl benzoate, benzyl alcohol, ethyl benzoate, triacetin, N-methyl-2-pyrrolidone, or a combination of two or more thereof.
Dependencies are inferred from the claim text.